Cargando…

Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program

PURPOSE: Safety-net health systems, which serve a disproportionate share of patients at high risk for hepatitis C virus (HCV) infection, may use revenue generated by the federal drug discount pricing program, known as 340B, to support multidisciplinary care. Budgetary impacts of repealing the drug-p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jones, Eric A., Linas, Benjamin P., Truong, Ve, Burgess, James F., Lasser, Karen E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417774/ https://www.ncbi.nlm.nih.gov/pubmed/30870475 http://dx.doi.org/10.1371/journal.pone.0213745

Ejemplares similares

Access to the 340B Drug Pricing Program: is there evidence of strategic hospital behavior?
por: Mulligan, Karen, et al.
Publicado: (2021)

Outcomes of the 340B Drug Pricing Program: A Scoping Review
por: Knox, Ryan P., et al.
Publicado: (2023)

A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program
por: Lee, Kristen S., et al.
Publicado: (2020)

Trends in 340B Drug Pricing Program Contract Growth Among Retail Pharmacies From 2009 to 2022
por: Nikpay, Sayeh, et al.
Publicado: (2023)

Assessment of US Pharmacies Contracted With Health Care Institutions Under the 340B Drug Pricing Program by Neighborhood Socioeconomic Characteristics
por: Lin, John K., et al.
Publicado: (2022)

A Revolution in Treatment for Hepatitis C Infection: Mitigating the Budgetary Impact
por: Marseille, Elliot, et al.
Publicado: (2016)

Budgetary control in academic libraries
por: Martin, Murray S
Publicado: (1978)

Notes and Proposals on Budgetary Calculations
Publicado: (1962)

Budgetary Arrangements for the ISR Programme in the Future
Publicado: (1970)

Budgetary Arrangements for the ISR Programme in the Future
Publicado: (1970)

Budgetary Arrangements for the ISR Programme in the Future
Publicado: (1970)

Examination of the Consequences of Suggested Budgetary Cuts
Publicado: (1957)

Comparison of Generic Prescribing Patterns Among 340B-Eligible and Non-340B Prescribers in the Medicare Part D Program
por: Dickson, Sean, et al.
Publicado: (2023)

Sugammadex: Appropriate Use in the Context of Budgetary Constraints
por: Cammu, Guy
Publicado: (2018)

Drug Pricing Evolution in Hepatitis C
por: Vernaz, Nathalie, et al.
Publicado: (2016)

Potential epidemiologic, economic, and budgetary impacts of current rates of hepatitis C treatment in medicare and non‐medicare populations
por: Wittenborn, John, et al.
Publicado: (2017)

Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain
por: Jiménez-Ruiz, Carlos A, et al.
Publicado: (2015)

Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis
por: Mulder, Christiaan, et al.
Publicado: (2022)

The 340B Program and Health Disparities Among Medicare Beneficiaries With Chronic Asthma
por: Tripp, Amanda S, et al.
Publicado: (2023)

Achieving high value care for all and the perverse incentives of 340B price agreements
por: Whittington, Melanie D., et al.
Publicado: (2018)

Acceptability of Rapid Point-of-Care Hepatitis C Tests Among People Who Inject Drugs and Utilize Syringe-Exchange Programs
por: Barocas, Joshua A., et al.
Publicado: (2016)

Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016
por: Conti, Rena M., et al.
Publicado: (2019)

Association Between New 340B Program Participation and Commercial Insurance Spending on Outpatient Biologic Oncology Drugs
por: Chang, Jessica, et al.
Publicado: (2023)

Projection of budgetary savings to US state Medicaid programs from reduced nursing home use due to an Alzheimer's disease treatment
por: Lam, Jenny, et al.
Publicado: (2021)

Proposal for an expanded methodology for presenting the Organization’s financial and budgetary position
Publicado: (2021)

Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone(®)) in Spain
por: Martinez-Raga, Jose, et al.
Publicado: (2012)

WHO's budgetary allocations and burden of disease: a comparative analysis
por: Stuckler, David, et al.
Publicado: (2008)

Evaluation of 340B prescription assistance program on healthcare use in chronic obstructive pulmonary disease
por: Taliaferro, Leah M., et al.
Publicado: (2023)

Request for Authorization to Exceed the Budgetary Appropriation for the Symposium Held in June 1956
Publicado: (1956)

The budgetary impact of alemtuzumab in multiple sclerosis in Quito, Ecuador. Payer’s perspective
por: Pastor-Quirós, Luis J., et al.
Publicado: (2021)

Comparison of Price Index Methods and Drug Price Inflation Estimates for Hepatitis C Virus Medications
por: Mattingly, T. Joseph, et al.
Publicado: (2023)

Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door
por: Yang, Y. Tony, et al.
Publicado: (2016)

Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States
por: Malouin, Rebecca A., et al.
Publicado: (2018)

Summary of the Budgetary and Financial Situation after the 99th Meeting of the Finance Committee
Publicado: (1969)

Process evaluation of counseling delivered by a patient navigator in an efficacious smoking cessation intervention among low-income primary care patients
por: Quintiliani, Lisa M., et al.
Publicado: (2019)

Essential managerial skills for financial and budgetary management in medical universities: The top managers' perspective
por: Javani, Ali, et al.
Publicado: (2017)

Budgetary targets as cost-containment measure in the Swiss healthcare system? Lessons from abroad()
por: Braendle, Thomas, et al.
Publicado: (2020)

PHL2/340: West of Scotland Primary Care Internet Project
por: Wilson, S
Publicado: (1999)

Hepatitis C Treatment Outcomes for People Who Inject Drugs Treated in an Accessible Care Program Located at a Syringe Service Program
por: Eckhardt, Benjamin J, et al.
Publicado: (2018)

340 "Sepan cuantos-- ", 1959-1979.
Publicado: (1979)

Cannot write session to /tmp/vufind_sessions/sess_j39mi4r1ngk98qnlgele7f1ibr